Latest news with #NationalBreastandCervicalCancerEarlyDetectionProgram
Yahoo
28-05-2025
- Business
- Yahoo
Susan G. Komen® Urges Swift Passage of Reintroduced SCREENS for Cancer Act
Legislation Ensures Access to Life Saving Breast Cancer Care WASHINGTON, May 28, 2025--(BUSINESS WIRE)--Susan G. Komen®, the world's leading breast cancer organization, commends members of the U.S. Senate for reintroducing the Screening for Communities to Receive Early and Equitable Needed Services (SCREENS) for Cancer Act. The legislation is led by Senators Tammy Baldwin (D-WI) and Susan Collins (R-ME). The SCREENS for Cancer Act reauthorizes a critical program – the National Breast and Cervical Cancer Early Detection Program (NBCCEDP) – that helps women across the country with low incomes who do not have adequate insurance gain access to timely breast and cervical cancer screening, diagnostic, and treatment services. The reintroduction of the SCREENS for Cancer Act after the release of the Trump Administration's fiscal year 2026 (FY26) budget proposal which called to eliminate all federal funding for critical cancer prevention and control programs, including NBCCEDP. Without access to early detection programs, many people without adequate insurance are forced to delay or forgo screenings, which could lead to later-stage breast cancer diagnoses, making it up to five times more expensive to treat and more likely to result in poor outcomes. The SCREENS for Cancer Act and congressional support for NBCCEDP is more important than ever amongst this call to eliminate funding. "Access to timely, high-quality screening and diagnostic services is critical for saving lives, yet far too many people—especially those without adequate insurance—face delays or are unable to access this essential care," said Molly Guthrie, VP of Policy & Advocacy at Susan G. Komen. "The SCREENS for Cancer Act would help enable earlier detection of breast cancer when treatment options are more effective, and the prognosis is better. Komen is grateful for the leadership of Senators Baldwin and Collins on this legislation and urges Congress to pass it quickly." "Nearly every American's life has been touched by a devastating cancer diagnosis, and early detection is one of the best tools we have to save lives. No Wisconsinite should miss regular screenings because of cost," said Senator Baldwin. "That's why I'm proud to lead this legislation with my Republican colleague to help detect cancers earlier, save lives, and ensure more Americans get the care they need at a price they can afford." Since its founding in 1991, NBCCEDP-funded programs have served more than 6.4 million individuals across the country and provided more than 16.5 million breast and cervical cancer screening examinations, resulting in the diagnosis of nearly 80,000 invasive breast cancers. The program also provides public education, outreach, patient navigation and care coordination to increase breast and cervical cancer screening rates and reach underserved, vulnerable populations. "Cancer prevention and screening programs are vital because the earlier the disease is caught, the better the prognosis," said Senator Collins. "The NBCCEDP provides thousands of uninsured and underinsured Mainers with breast and cervical cancer screening, diagnostic, and treatment services each year. Our bipartisan SCREENS for Cancer Act would reauthorize and strengthen this critical program, which has helped nearly 4,000 women in Maine receive a total of 8,198 screening tests over the past five years." This bill had widespread, bipartisan support in the 118th Congress and passed key committees in both the Senate and House of Representatives. Joining Senators Baldwin and Collins are Representative Joe Morelle (D-NY-25) and Brian Fitzpatrick (R-PA-1) who reintroduced the bill in the House earlier in March. Susan G. Komen urges the 119th Congress to pass the SCREENS for Cancer Act without delay. Immediate action is critical to make meaningful progress in the fight against breast cancer and to ensure that all Americans have access to the screenings they need for early, life-saving intervention. Learn more about Susan G. Komen's Center for Public Policy at: About Susan G. Komen® Susan G. Komen® is the world's leading nonprofit breast cancer organization, working to save lives and end breast cancer forever. Komen has an unmatched, comprehensive 360-degree approach to fighting this disease across all fronts and supporting millions of people in the U.S. and in countries worldwide. We advocate for patients, drive research breakthroughs, improve access to high-quality care, offer direct patient support and empower people with trustworthy information. Founded by Nancy G. Brinker, who promised her sister, Susan G. Komen, that she would end the disease that claimed Suzy's life, Komen remains committed to supporting those affected by breast cancer today, while tirelessly searching for tomorrow's cures. Visit or call 1-877 GO KOMEN. Connect with us on social at View source version on Contacts Cristobal MartinezSusan G. Komen(972) 701-2135cmartinez@ Sign in to access your portfolio
Business Wire
28-05-2025
- Health
- Business Wire
Susan G. Komen ® Urges Swift Passage of Reintroduced SCREENS for Cancer Act
WASHINGTON--(BUSINESS WIRE)-- Susan G. Komen ®, the world's leading breast cancer organization, commends members of the U.S. Senate for reintroducing the Screening for Communities to Receive Early and Equitable Needed Services (SCREENS) for Cancer Act. The legislation is led by Senators Tammy Baldwin (D-WI) and Susan Collins (R-ME). The SCREENS for Cancer Act reauthorizes a critical program – the National Breast and Cervical Cancer Early Detection Program (NBCCEDP) – that helps women across the country with low incomes who do not have adequate insurance gain access to timely breast and cervical cancer screening, diagnostic, and treatment services. The reintroduction of the SCREENS for Cancer Act after the release of the Trump Administration's fiscal year 2026 (FY26) budget proposal which called to eliminate all federal funding for critical cancer prevention and control programs, including NBCCEDP. Without access to early detection programs, many people without adequate insurance are forced to delay or forgo screenings, which could lead to later-stage breast cancer diagnoses, making it up to five times more expensive to treat and more likely to result in poor outcomes. The SCREENS for Cancer Act and congressional support for NBCCEDP is more important than ever amongst this call to eliminate funding. 'Access to timely, high-quality screening and diagnostic services is critical for saving lives, yet far too many people—especially those without adequate insurance—face delays or are unable to access this essential care,' said Molly Guthrie, VP of Policy & Advocacy at Susan G. Komen. 'The SCREENS for Cancer Act would help enable earlier detection of breast cancer when treatment options are more effective, and the prognosis is better. Komen is grateful for the leadership of Senators Baldwin and Collins on this legislation and urges Congress to pass it quickly.' 'Nearly every American's life has been touched by a devastating cancer diagnosis, and early detection is one of the best tools we have to save lives. No Wisconsinite should miss regular screenings because of cost,' said Senator Baldwin. 'That's why I'm proud to lead this legislation with my Republican colleague to help detect cancers earlier, save lives, and ensure more Americans get the care they need at a price they can afford.' Since its founding in 1991, NBCCEDP-funded programs have served more than 6.4 million individuals across the country and provided more than 16.5 million breast and cervical cancer screening examinations, resulting in the diagnosis of nearly 80,000 invasive breast cancers. The program also provides public education, outreach, patient navigation and care coordination to increase breast and cervical cancer screening rates and reach underserved, vulnerable populations. 'Cancer prevention and screening programs are vital because the earlier the disease is caught, the better the prognosis,' said Senator Collins. 'The NBCCEDP provides thousands of uninsured and underinsured Mainers with breast and cervical cancer screening, diagnostic, and treatment services each year. Our bipartisan SCREENS for Cancer Act would reauthorize and strengthen this critical program, which has helped nearly 4,000 women in Maine receive a total of 8,198 screening tests over the past five years.' This bill had widespread, bipartisan support in the 118 th Congress and passed key committees in both the Senate and House of Representatives. Joining Senators Baldwin and Collins are Representative Joe Morelle (D-NY-25) and Brian Fitzpatrick (R-PA-1) who reintroduced the bill in the House earlier in March. Susan G. Komen urges the 119 th Congress to pass the SCREENS for Cancer Act without delay. Immediate action is critical to make meaningful progress in the fight against breast cancer and to ensure that all Americans have access to the screenings they need for early, life-saving intervention. Susan G. Komen ® is the world's leading nonprofit breast cancer organization, working to save lives and end breast cancer forever. Komen has an unmatched, comprehensive 360-degree approach to fighting this disease across all fronts and supporting millions of people in the U.S. and in countries worldwide. We advocate for patients, drive research breakthroughs, improve access to high-quality care, offer direct patient support and empower people with trustworthy information. Founded by Nancy G. Brinker, who promised her sister, Susan G. Komen, that she would end the disease that claimed Suzy's life, Komen remains committed to supporting those affected by breast cancer today, while tirelessly searching for tomorrow's cures. Visit or call 1-877 GO KOMEN. Connect with us on social at
Business Wire
02-05-2025
- Health
- Business Wire
Susan G. Komen Deeply Concerned About Proposed Cuts in FY26 Federal Budget Proposal
WASHINGTON--(BUSINESS WIRE)-- Susan G. Komen®, the world's leading breast cancer organization, is deeply alarmed by the Trump Administration's budget proposal for fiscal year 2026 (FY26) which would eliminate all funding for critical cancer prevention and control programs, including the National Breast and Cervical Cancer Early Detection Program (NBCCEDP), and significantly cut life-saving research at the Department of Health and Human Services (HHS), including the National Institutes of Health (NIH). An estimated 319,750 people in the United States will be diagnosed with breast cancer and nearly 43,000 will die from the disease this year alone. An estimated 319,750 people in the United States will be diagnosed with breast cancer and nearly 43,000 will die from the disease this year alone. Regular screening enables us to detect potential cancers at earlier stages and refer patients to further care, often yielding better outcomes for patients and resulting in decreased financial pressure on our healthcare system. Congress established NBCCEDP which assists individuals with low-incomes and no or inadequate insurance gain access to breast and cervical cancer screening and diagnostic services that are free or low-cost. For over 30 years, NBCCEDP funded programs have served more than 6.4 million people and provided more than 16.5 million breast and cervical cancer screening examinations. To date, NBCCEDP has diagnosed over 79,000 invasive breast cancers, over 25,000 premalignant breast lesions, more than 5,000 invasive cervical cancers, and over 248,000 premalignant cervical lesions. Without access to early detection programs, many people who are uninsured are forced to delay or forgo screenings, which could lead to late-stage breast cancer diagnoses. This delay can mean that a person may not seek care until the cancer has spread beyond the breast, making it up to five times more expensive, harder to treat, and more likely to result in poor outcomes. Investment in early detection is an investment in not just the patient's future but a more efficient healthcare system. Unfortunately, the President's FY26 budget proposal does not invest in the American people's fight against breast cancer. The budget proposal would end federal funding for NBCCEDP in addition to other incredibly important programs to the cancer community, including the National Program of Cancer Registries, the National Comprehensive Cancer Control Program, and the Colorectal Cancer Control Program. If adopted, the FY26 budget proposal will set the cancer screening and detection back decades and result in increased deaths from cancer. In addition to proposing to eliminate NBCCEDP funding, the proposal would decimate investment in medical research at the NIH. Biomedical research has been the driving force behind decades of advances that have improved the health of people in every corner of America – including the lives of those affected by breast cancer, leading to new and better cures, diagnostics, and preventive interventions – and has positioned the United States as the global leader in biomedical breakthroughs, the development of new technologies, and innovative treatments. Additionally, NIH research funding helps fuel economic growth— every dollar invested by the NIH in research generates $2.56 in new economic activity. Alarmingly, proposed cuts are already prompting top scientific talent to consider careers outside the U.S. Put simply, cuts of this magnitude to NIH are shortsighted for both the American healthcare system and the economy. Komen urges Congress to work in a bicameral, bipartisan manner to fund the federal government with robust investments in our nation's health. While we support a healthcare and public health system that works efficiently and effectively for everyone—slashing funding across HHS is dangerous and will harm the breast cancer community. Federal investments in early detection and research are not just compassionate—they are practical, cost-effective, and essential to the health of the nation. Susan G. Komen ® is the world's leading nonprofit breast cancer organization, working to save lives and end breast cancer forever. Komen has an unmatched, comprehensive 360-degree approach to fighting this disease across all fronts and supporting millions of people in the U.S. and in countries worldwide. We advocate for patients, drive research breakthroughs, improve access to high-quality care, offer direct patient support and empower people with trustworthy information. Founded by Nancy G. Brinker, who promised her sister, Susan G. Komen, that she would end the disease that claimed Suzy's life, Komen remains committed to supporting those affected by breast cancer today, while tirelessly searching for tomorrow's cures. Visit or call 1-877 GO KOMEN. Connect with us on social at
Yahoo
12-04-2025
- Health
- Yahoo
Women's Health Diagnostics Market Size to Hit USD 49.00 Billion by 2032, Driven by Technological Advancements and Rising Awareness
According to SNS Insider, the global Women's Health Diagnostics Market growth is fueled by growing emphasis on early disease detection and expanding access to healthcare diagnostics. Austin, April 12, 2025 (GLOBE NEWSWIRE) -- Women's Health Diagnostics Market Size & Growth Analysis: According to the latest report from SNS Insider, the Women's Health Diagnostics Market was valued at USD 25.30 billion in 2023 and is anticipated to reach USD 49.00 billion by 2032, expanding at a CAGR of 7.64% during the forecast period of 2024 to 2032. The market's upward trajectory is being fueled by increased awareness of women's health issues, advancements in diagnostic technologies, and the growing prevalence of chronic and lifestyle-related diseases among women. Innovations in genetic testing, imaging technologies, and biomarker research are transforming how conditions like breast cancer, cervical cancer, and reproductive health disorders are diagnosed and a Sample Report of Women's Health Diagnostics Market@ Market analysis The increasing prevalence of diseases such as breast cancer, cervical cancer, and osteoporosis is driving demand for early detection, making accurate and efficient diagnostic solutions a priority. High healthcare expenditure, government funding for women's health programs, and early adoption of advanced diagnostic technologies in the region driving its growth, as the US held a 38% share of the global market in 2023. Breast cancer is the most common cancer among American women, with over 300,000 new cases each year reported according to the Centers for Disease Control and Prevention (CDC), fuelling the demand for early diagnostic solutions. Increasing awareness, technological developments, and growing healthcare investments are helping the global market for early detection of diseases in women, such as breast cancer, cervical cancer, and osteoporosis, achieve strong growth. The market is dominated by the United States with a 38% share in 2023 with extensive healthcare spending, strong government programs e.g. the National Breast and Cervical Cancer Early Detection Program (NBCCEDP), and early adoption of innovative diagnostic tools e.g. 3D mammography, HPV testing, and AI-based imaging systems. Technological innovation is a key market driver, with advancements like liquid biopsies, genetic testing, and portable bone density scanners enhancing diagnostic accuracy and accessibility. Moreover, artificial intelligence (AI) in imaging and diagnostics helps mitigate human errors while increasing early detection rates. Increasing awareness via advocacy organizations and digital health platforms is also driving market growth because it motivates more women to opt for regular screenings. However, challenges such as high diagnostic costs, disparities in healthcare access, and cultural barriers in certain regions may hinder growth. Key Women's Health Diagnostics Companies Profiled in the Report F. Hoffmann-La Roche Ltd. – cobas HPV Test, cobas Mammography Solutions, Elecsys Anti-Müllerian Hormone (AMH) Test, Ventana HER2 Assay Hologic, Inc. – ThinPrep Pap Test, Genius 3D Mammography System, Aptima HPV Assay, Panther System Quest Diagnostics Incorporated – BRCAvantage (BRCA1/BRCA2 Testing), HPV and Pap Co-testing, Comprehensive Hormone Panel for Women's Health, MaterniT 21 PLUS (NIPT) Abbott – Alinity m HPV Assay, ARCHITECT Estradiol Assay, i-STAT Total β-hCG Test, RealTime High-Risk HPV Test BD (Becton, Dickinson, and Company) – BD SurePath Liquid-based Pap Test, BD Onclarity HPV Assay, BD MAX Vaginal Panel, BD Affirm VPIII Microbial Identification GE Healthcare – Senographe Pristina Mammography System, Invenia ABUS (Automated Breast Ultrasound System), Voluson Ultrasound Series Koninklijke Philips N.V. – Affiniti Ultrasound System, Epiq Women's Health Ultrasound, MicroDose SI Mammography Aspira Women's Health – OVA1 Test, OVERA Test Thermo Fisher Scientific Inc. – Ion Torrent NGS for Women's Health, ProFlex PCR System, SureTect Real-Time PCR Assays Cardinal Health, Inc. – Women's Health Point-of-Care Testing Solutions, Pregnancy & Fertility Test Kits Siemens AG – Mammomat Revelation Mammography System, ADVIA Centaur HPV Assay, Atellica IM Estradiol Assay PerkinElmer Inc. – DELFIA Xpress hCG Test, Vanadis NIPT, Eeva Test for IVF Women's Health Diagnostics Market Report Scope Report Attributes Details Market Size in 2023 US$ 25.30 billion Market Size by 2032 US$ 49.00 billion CAGR CAGR of 7.64% From 2024 to 2032 Base Year 2023 Forecast Period 2024-2032 Historical Data 2020-2022 Key Regional Coverage North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East]), Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia Rest of Latin America) Market Segmentation By Application In 2023, the cancer diagnostics segment dominated the market with a revenue share of 33.03%, which can be attributed to the increasing prevalence of breast and cervical cancers. The cancer diagnosis segment seems to lead as options like mammography, MRI, and liquid biopsy tests for breast cancer are few among many available, adding up by government-funded screening initiatives. One in 8 women in the U.S. will develop breast cancer, according to the CDC, creating a need for early detection tools. Diagnostics for cervical cancer like Pap smears and HPV testing are another big contributor, with the WHO advocating for global elimination via more widespread screening. Other critical applications that rely on imaging include infectious disease testing (HPV and HIV), osteoporosis diagnostics (DEXA), and pregnancy & fertility testing (ultrasound or hormone assays). Innovative technologies like AI-embedded imaging and portable diagnostic devices are also accelerating market growth. By End-Use The market was dominated by hospitals in 2023, with the highest revenue share, and this trend is expected to continue, as hospitals remain the primary servicing locations for a range of diagnostic tests. Showcasing advanced imaging systems, reproductive radiologists, and high patient volumes, national hospital systems are critical drug and diagnostic partners in women's health. Diagnostic labs ranked a close second, spurred on by the trend of outsourcing specific testing, such as genomic profiling or hormone level assessment. Adoptions in clinics and home-care environments are being spurred by the rise of point-of-care (POC) testing home-based HPV and fertility tests that are FDA-approved are becoming increasingly popular. Let's not forget about government initiatives either, like the free mammogram programs in the U.S. and Europe, which bolster hospital-based diagnostics. Need Any Customization Research on Women's Health Diagnostics Market, Enquire Now@ Women's Health Diagnostics Market Segmentation By Application Cancer Infectious diseases Osteoporosis Pregnancy & fertility Prenatal By End-Use Hospitals Laboratory Home care Others Regional Analysis North America also dominated the market in 2023, accounted for 44.31% of global revenue, the U.S. accounting for 38%. It is due to high health care costs, strong diagnostic infrastructure, and government programs such as the National Breast and Cervical Cancer Early Detection Program (NBCCEDP). There are an estimated 300,000 new breast cancer cases diagnosed every year, by the Centers for Disease Control and Prevention, and demand for early detection tools is high. Europe had the second most significant share, as nations such as Germany and the U.K. promoted national cancer screening programs. The EU's Beating Cancer Plan set a target for 90% of eligible women across the bloc to receive breast cancer screenings by 2025, further driving up the adoption of diagnostics. The fastest-growing market is in the Asia-Pacific region, which is being driven by higher healthcare investment, growing awareness, and improved diagnostic facilities. Countries including India and China can see the case of HPV testing and transportable ultraviolet adoption, bolstered via authorities schemes like Ayushman Bharat. Recent Developments The next-generation 3D mammography system, launched by Hologic Inc., in 2024 with AI-powered imaging to improve early breast cancer diagnosis. In March 2024, Siemens Healthineers gained FDA approval for its high-risk human papillomavirus (HPV) DNA assay, advancing the accuracy of cervical cancer a Single-User PDF of Women's Health Diagnostics Market Analysis & Outlook Report 2024-2032@ Table of Contents – Major Key Points 1. Introduction 2. Executive Summary 3. Research Methodology 4. Market Dynamics Impact Analysis 5. Statistical Insights and Trends Reporting 5.1 Incidence and Prevalence of Women's Health Conditions (2023), by Region 5.2 Technological Advancements in Women's Health Diagnostics (2023-2032) 5.3 Adoption Rate of Early Screening Programs and Preventive Diagnostics (2023), by Region 5.4 Growth Trends in Home-Based and Point-of-Care Testing for Women's Health (2020-2032) 5.5 Regulatory and Policy Trends Impacting Women's Health Diagnostics (2023-2032) 6. Competitive Landscape 7. Women's Health Diagnostics Market by Application 8. Women's Health Diagnostics Market by End-Use 9. Regional Analysis 10. Company Profiles 11. Use Cases and Best Practices 12. Conclusion Access Complete Report Details of Women's Health Diagnostics Market Analysis & Outlook 2024-2032@ [For more information or need any customization research mail us at info@ About Us: SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world. CONTACT: Contact Us: Jagney Dave - Vice President of Client Engagement Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)Sign in to access your portfolio
Yahoo
04-03-2025
- Health
- Yahoo
Cervical cancer prevention in Odessa
ODESSA, Texas (KMID/KPEJ) – As of October 24, 2000, President William Clinton signed into law the Breast and Cervical Cancer Prevention and Treatment Act of 2000 (Public Law 106-354). This Act gives states the option to provide medical assistance through Medicaid to women who have been screened for and found to have breast or cervical cancer, including precancerous conditions, through the National Breast and Cervical Cancer Early Detection Program (NBCCEDP). The Permian Women's Center advises that women ages 25 to 65 should get a Pap test every three years or an HPV test every five years, as a way to prevent health complications. In the Basin the Ector County Health Department offers free cervical cancer screenings on Thursdays, by appointment only, from 1 p.m. to 3 p.m. The requirements for free screening at ECHD are: Female 21-65 years old Must have a Texas address No prior diagnosis of cervical cancer For more information or to book an appointment you can visit the Ector County Health Department. In Midland, you can visit Midland Women's Clinic or Gynecologic Oncology at Texas Oncology-Midland Allison Cancer Center for testing. Free informational resources online include Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
